About
Leadership
Executive Team
Board of Directors
Facilities
Therapeutic Areas Overview
Central Nervous System
Fibromyalgia
Cocaine Intoxication
Migraine
Immunology
Organ Transplant Rejection
Gastro-Intestinal Cancers
Infectious Disease
COVID-19
Mpox (Monkey Pox)
Smallpox
Rare Disease
Prader-Willi Syndrome
Pipeline
Central Nervous System
TNX-102 SL
TNX-1300
TNX-1900
Immunology
TNX-1500
TNX-1700
Infectious Disease
TNX-801
TNX-1800
TNX-4200 CD45
Rare Disease
TNX-2900
Expanded Access Policy
Medicines
Clinical Trials
News & Events
Press Releases
Tonix in the News
Tonix Sponsored News
Investor Presentations
Scientific Presentations
IR Events
Op-eds
Investors
News & Events
Presentations
Investor Presentations
Scientific Presentations
Program Specific Presentations
Fact Sheet
Conference Materials
Multimedia
Financial Info
Stock Data
SEC Filings
Governance
Careers
Contact Us
Financial Information
Investors
Investors
Overview
News & Events
Press Releases
Tonix in the News
Tonix Sponsored News
IR Events
Email Alerts
Op-Eds
Presentations
Multimedia
Financial Info
Financial Results
Income Statement
Balance Sheet
Cash Flow
Stock Data
Quote
Charts
Historical Data
Analyst Coverage
SEC Filings
All SEC Filings
Annual Reports
Quarterly Reports
Section 16 Filings
Governance
Board of Directors
Board Committees
Governance Documents
Latest Financial Results
Q3 2024
Quarter Ended Sep 30, 2024
Earnings Release
PDF
HTML
10-Q
Filing
PDF
HTML
XBRL
ZIP
XLS
HTML
Latest 10-K
View HTML
View PDF
Financials
View the latest financials
Income Statement
Balance Sheet
Cash Flow
